In today’s complex pharmaceutical landscape, drug sponsors bring extraordinary expertise to their products and platforms.
Their knowledge runs deep within their portfolios but may often be confined to a specific focus … and may not include the myriad challenges that occur during scale-up and commercialisation.
When these unexpected challenges do arise, they can cause significant delays and the need to address resource consumption.
Contract development and manufacturing organisations (CDMOs) operate in a different environment altogether, reports Melanie Cerullo, Chief Quality Officer at Kindeva.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.